This study aimed to evaluate the sensitivity and specificity of subepidermal moisture (SEM), a biomarker employed for early detection of pressure injuries (PI), compared to the “Gold Standard” of clinical skin and tissue assessment (STA), and to characterize the timing of SEM changes relative to the diagnosis of a PI. This blinded, longitudinal, prospective clinical study enrolled 189 patients (n = 182 in intent‐to‐treat [ITT]) at acute and post‐acute sites (9 USA, 3 UK). Data were collected from patients' heels and sacrums using a biocapacitance measurement device beginning at admission and continuing for a minimum of 6 days to: (a) the patient developing a PI, (b) discharge from care, or (c) a maximum of 21 days. Standard of care clinical interventions prevailed, uninterrupted. Principal investigators oversaw the study at each site. Blinded Generalists gathered SEM data, and blinded Specialists diagnosed the presence or absence of PIs. Of the ITT population, 26.4% developed a PI during the study; 66.7% classified as Stage 1 injuries, 23% deep tissue injuries, the remaining being Stage 2 or Unstageable. Sensitivity was 87.5% (95% CI: 74.8%‐95.3%) and specificity was 32.9% (95% CI: 28.3%‐37.8%). Area under the receiver operating characteristic curve (AUC) was 0.6713 (95% CI 0.5969‐0.7457, P < .001). SEM changes were observed 4.7 (± 2.4 days) earlier than diagnosis of a PI via STA alone. Latency between the SEM biomarker and later onset of a PI, in combination with standard of care interventions administered to at‐risk patients, may have confounded specificity. Aggregate SEM sensitivity and specificity and 67.13% AUC exceeded that of clinical judgment alone. While acknowledging specificity limitations, these data suggest that SEM biocapacitance measures can complement STAs, facilitate earlier identification of the risk of specific anatomies developing PIs, and inform earlier anatomy‐specific intervention decisions than STAs alone. Future work should include cost‐consequence analyses of SEM informed interventions.
Pressure injuries (PI) are a widespread and serious complication of reduced patient mobility. Annually, PIs occur in more than 2.5 million US patients, of whom approximately 60 000 die due to infection and other sequelae.11 Due to the substantial impacts of PIs on patient quality of life, recovery, and lengths of stay, PI prevention is prioritized by providers and policy makers.22, 33, 44, 55 The United States' Agency for Healthcare Research and Quality' (AHRQ) statistics, however, show PIs being the only Hospital Acquired Condition whose incidence worsened during 2014‐2017.66 The overall costs of PIs in the United States are estimated to exceed $26.8 billion,77, 88, 99 with per‐patient costs ranging from $500 to $70 000.1010
A combination of PI risk assessments, supplemented by skin and tissue assessments (STAs) and mechanical offloading (such as patient repositioning and the use of pressure redistributing mattresses and medical devices) comprises most PI prevention programs.11 The use, benefits, and limitations of risk assessment tools (RATs) are well documented elsewhere1111, 1212, 1313, 1414, 1515 and other than their use in screening patients for initial risk, are not the subject of this manuscript. STA appraises skin color, blanchability, temperature, hardness, and other visible or palpable indicators of injury. The international pressure ulcer advisory panel's—US National Pressure Ulcer Advisory Panel/European Pressure Ulcer Advisory Panel/Pan Pacific Pressure Injury Alliance (NPUAP/EPUAP/PPPIA)—global 2014 Clinical Practice Guideline, states, “The condition of skin and underlying tissue can serve as an indicator of early signs of pressure damage, therefore routine STA provide an opportunity for early identification and treatment of skin alterations, especially pressure ulcers.”1111 Clinical judgment of nurses, informed by risk tools and STA, however, “achieved inadequate capacity to assess PU risk”1212 and suffered from “high inter‐examiner variability.”1212, 1313 Clinical judgment has a sensitivity of 50.6% and specificity of 60.1%.1313 Because of the skill dependency of STA, correct identification of a stage I pressure ulcer has been observed as low as 60% in a diverse group of 1452 nurses.1414 Latency of visual and palpable signs do not address nonvisible cues of tissue damage: PI often occur without prior visual and palpable cues appearing in time to prevent them. In patients at high risk for pressure ulcer formation, nonblanchable erythema can develop in as little as 2 hours from injury.1515 Due to the subjective, latent nature of STAs, there is a clear need for an objective, point‐of‐care tool for diagnosing or assessing developing PIs on at‐risk patients.
A change in subepidermal moisture (SEM) due to local edema or accumulation of interstitial fluid is a biomarker of a developing PI and precedes the appearance of visible or palpable skin changes by approximately 3‐10 days.1616, 1717, 1818, 1919, 2020, 2121 Electrical biocapacitance of human tissue varies with interstitial moisture content; therefore, SEM changes manifest as changes in biocapacitance, which can be measured by point‐of‐care devices.1919, 2222, 2323 A biocapacitance measurement device2424 that has previously shown inter‐operator and inter‐device reliability in detection of SEM changes (R ≥ 0.8), as well as agreement with ultrasound detection of hypoechoic lesions consistent with PIs, supporting the potential utility of this device.1919, 2121, 2525 Independent studies suggest that a biocapacitance measurement is a useful adjunct to clinical STAs, particularly for prediction of developing PIs, and the data, when used to initiate anatomy‐specific interventions may reduce the incidence of hospital‐acquired PI.1818, 2020, 2626, 2727, 2828, 2929 The comparative sensitivity and specificity of biocapacitance measurements in detecting PIs relative to the current reference standard of clinical STA is however, not well characterized. This longitudinal clinical study was conducted to evaluate the sensitivity and specificity of assessing SEM using a biocapacitance measurement device in accordance with regulatory guidelines for new diagnostic tests,3030 and further, to characterize the timing of SEM changes compared to the diagnosis of PI by STA scales.
This multisite, blinded, prospective, longitudinal clinical study was conducted at 12 inpatient facilities (six acute care and three post‐acute care settings in the United States [77.8%; n = 147] and three acute care settings in the United Kingdom [22.2%; n = 42]) consistent with good clinical practices standards set by the USA's Code of Federal Regulations (21 CFR 812—Investigational Device Exemption; United States 21 CFR 50—Protection of Human Subjects; United States 21 CFR 56—Institutional Review Boards), International Standards (ISO 14155:2011—Clinical Investigation of Medical Devices for Human Subjects—Good Clinical Practice); and, the International Conference on Harmonization of Good Clinical Practice Guidelines and the Declaration of Helsinki.
Subjects were tracked from enrollment with no observed PI to discharge. Discharge was precipitated by any of three events: (a) confirmation of a pressure injury by an expert “Specialist”; (b) discharge from the facility after a minimum of 6 days of observation; or (c) satisfying the maximum enrollment of 21 days. The prospective design tested two objectives; the first, that measured changes in the SEM biomarker are associated with the later manifestation of a PI (stage 1, stage 2, deep tissue injury) to 70% sensitivity and 55% specificity with 95% confidence compared to the reference standard of clinical STA. Second, that the SEM biomarker gives notification of such changes prior to an expert skin assessed PI manifesting at the skin's surface.
A subtle distinction of consequence is that the first objective was based on the detection of a biomarker (SEM) of the later onset of a stageable PI. No designation of a PI preceding stage 1 in the etiological process exists in any published guidelines: Stage 1 being the first available stage of PI useable to establish sensitivity and specificity.
Protocol design was informed by an independent investigator study2020 which pointed toward viability of clinical interpretation using the threshold cutoff value of the biocapacitance device (device) used in this study (Δ ≥0.6, explained below). O'Brien's study demonstrated that the device detects changes in pressure injured skin and tissue earlier than nurses' STA alone. Of the 47 patients enrolled in O'Brien's study, 40.43% (n = 19) study participants with consecutive days of elevated SEM levels (defined in O'Brien's study as, “a difference of greater than 0.5 between the lowest and highest [SEM] values recorded”. Although using different descriptions of the delta calculation, the definitions of the SEM delta as >0.5 or Δ ≥0.6 are mathematically equivalent), went on to develop signs of a pressure injury. Further, the use of the device identified changes to the SEM biomarker on average 3.9 days earlier than the nurses' STAs confirming a PI.2020
Study participants provided informed consent in writing. Three categories of clinical staff were organized to execute the trial at each site. Each site's principal investigator, or their formally appointed designee, oversaw the conduct of the entire trial for their site. “Specialists,” comprising experienced wound care specialists with accreditation in wound and ostomy or tissue viability care performed risk, skin, and PI diagnoses. Diagnoses by Specialists formed the “gold standard” of the existence or absence of a PI. It was against these gold standard diagnoses that device readings were evaluated. SEM biocapacitance measurements were performed by a separate group of, “Generalists” who received training in operation of the device by the device manufacturer and were tested for proficiency prior to initiation of the study. Generalists were clinical practitioners, generally Registered Nurses, Surgical Assistants, and Medical Doctors and were prohibited for the purposes of the trial from participating in wound care related clinical decisions for enrolled patients. Specialists and Generalists' data were blinded from each other. Each site's protocol compliance and data integrity were overseen and audited by a, “Study Coordinator.” All data were loaded to Medrio, an electronic data management system (Medrio Inc., California, USA), and locked; consistent with good clinical practices. A full post hoc audit of all data points was conducted by a Regulatory Body; four minor audit findings were noted relating to two sites, all of which were immediately able to be corrected. No findings affected the integrity of the data. No audit findings were noted for the Sponsor.
Withholding “standard of care” prevention or treatment interventions from enrolled subjects would have been unethical. Interventions were applied to all patients consistent with facility Standard of Care protocols. No interventions were permitted to be withheld nor were any interventions triggered by device readings. Data about such interventions were collected at every visit to allow assessment of potentially confounding effects.
Etiological studies show that early pressure damage does not always manifest into a visible PI.1919, 3131, 3232, 3333 Researchers of early stage PIs and PI biomechanics demonstrated the inherent reversible nature of early pressure damage.1919, 3131, 3232, 3333 Reversibility and self‐resolution are known phenomena PI.1919, 3131, 3232, 3333 Some early damage will progress to a PI and some will reverse back to a healthy state, depending on a variety of factors including a patient's overall health and whether an intervention is taken to alleviate pressure and or shear. Moreover, some pressure damage can be (a) stable, (b) not progressing, or (c) reversing.3131 Ultimately this means that increases in SEM delta values will not always lead to a PU, but a PI will be preceded by a change in SEM. Complications to end‐point analysis from these etiological realities were considered during trial design and in interpretation of the data.
Eligible study participants were patients ≥55 years of age who could be followed for at least six consecutive days and were determined to be at risk of developing PIs based on a score from validated risk assessment scales (Braden scale, < 15; Waterlow scale, ≥ 10; or Norton scale ≤18), poor nutrition, poor mobility (chair or bed‐bound), or completion of a recent medical procedure requiring subsequent immobilization (eg, surgery). The minimum follow‐up period of 6 days was chosen to provide a sufficient window of time for PI development, which evolves over approximately 1‐5 days.3434, 3535
Patients were excluded from study participation for any of the following: existing PIs; broken skin at either the sacrum or heels; moisture lesions or incontinence‐associated dermatitis (IAD); and biomechanical or other limitations preventing protocol‐driven assessments. Use of the device over broken skin was contraindicated, hence, in part, the exclusion of IAD.
Participants were followed for at least 6 and up to 21 days unless a pressure injury occurred in the intervening period, in which case they were discharged per protocol. No patients were followed after developing a PI in the study. Each day, participants were assessed for risk of a PI by Specialists using one of three established scales, depending on facilities' existing standard of care: the Braden Scale for Predicting Pressure Sore Risk,3838 the Waterlow Pressure Ulcer Prevention/Treatment Policy score,3939 or the Norton Pressure Sore Risk‐Assessment Scale Scoring System.4040 Skin temperature, erythema, edema, consistency (induration/hardness) in relation to surrounding tissue moisture, turgor, and health, as well as patient‐reported pain, were assessed in accordance with established guidelines.11, 4141 Incidents of PIs were staged as described elsewhere.11
SEM biocapacitance measurements were obtained from the sacrum ( Figure S1) and heels (Figure S2) . Results reflective of the underlying distribution of moisture depend on multiple readings from areas over and immediately contiguous to the anatomy. Six readings were therefore obtained from the sacral area and at least three readings were obtained from each heel.4242
The principles underlying the use of biocapacitance as an indirect measure of localized SEM and edema have been reviewed previously.1919, 4343 Biocapacitance varies with interstitial fluid content. Measurements of tissue biocapacitance may be used as an indicator of SEM.2424 The SEM Scanner (device) (Figure S3) (Bruin Biometrics, LLC, Los Angeles, CA, USA) technology assesses the fluid contents of epidermis and subdermal tissues. The device makes a direct steady‐state measurement of the capacitance of its sensor, which is affected by the equivalent dielectric constant of the material (ie, the layered tissue structures) that is within the electric field between the sensor electrodes to a depth of 0.15 in. (4 mm) and converts the biocapacitance from SI units to a score.2424 Two values are displayed on the device's screen, an individual value for each single scan, and after three readings are taken, the SEM Delta (ΔSEM), calculated as the difference of the minimum and maximum SEM values obtained at and immediately contiguous to an anatomical site. Calculation of a “delta” value compares measurements from several sites, some of which will be healthy tissue, compensates for systemic changes, overcomes the limitation of inter‐ and intra‐patient variability and provides a measure of tissue health condition.2424*
The range of device values is 0.2 to 4.0, with known tolerance of ±0.2. Prior sponsor studies determined a threshold delta value: Δ < 0.6 indicating lower risk for a pressure injury at the anatomy and Δ ≥ 0.6 indicative of increased risk for pressure ulcers at the anatomy being measured.
This study was powered to detect at least 70% sensitivity and 55% specificity of the device compared to the reference standard of clinical STA, with 95% confidence. A total of 189 patients were enrolled, of which 96.3% (n = 182) patients were listed as intent‐to‐treat (ITT) Figure S4. Within the 12 sites included in the study, the trials were completed in sites of service shown in Table 1.
Sensitivity and specificity analyses were completed on the 182 ITT population and on 170 per protocol (PP) patients. Division of enrolled participants into the ITT and per‐protocol (PP) analyses is detailed in Figure S4. The ITT analysis includes all subjects correctly enrolled regardless of subsequent nonmajor protocol deviations (eg, missed day by Specialist 37.1% and missed day by Generalist 29%). The PP cohort were subjects from the ITT population who met all inclusion and exclusion criteria, did not have protocol violations or deviations (eg, missed days, nonanalyzable data), and had both comparable days of data set by Specialists and Generalists. The PP cohort represented the highest quality data set; with complete data from all three anatomical locations and all daily evaluations completed by Specialists and Generalists for a minimum of 6 days with no gaps.
A Positive Detection was defined as, “Observation of two or more SEM deltas Δ ≥0.6 from three consecutive series of device readings prior to pressure ulcer diagnosis by clinical judgment of the Specialist”, and negative detection was defined as, “Observations of two or more SEM deltas Δ<0.6 from three consecutive series of device readings prior to no pressure ulcer diagnosis by clinical judgment of the Specialist.” For the purposes of endpoint analysis, a “Valid Series” of device measurements was considered when 3 days of device measurements were performed with no more than 1 day missing between these 3 days of measurements. A valid series comprised no more than four observation days of device measurements. The following are examples of valid series under this definition with “X” representing a study day with device measurements and “0” representing a day with no device measurements.
Example A: Three days of measurements without any missing days: X X X.
Example B: Four days of measurements with 1 day missing:
0 X X X
X 0 X X
X X 0 X
X X X 0
Positive and negative results from the Scanner were compared to Specialist assessments of patients' skin and tissue. These results formed the classes required to compute statistics for the first endpoint. Results were classed:
Specificity and sensitivity for both the ITT and PP populations were calculated based on counts of true negative (TN), true positive (TP), false negative (FN), and false positive (FP) findings using the method described by the US Food and Drug Administration,3030 such that:
Two‐sided 95% confidence intervals were calculated using the exact method. Statistical analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC) by an independent biostatistician according to a prospectively defined statistical analysis plan. At the request of the FDA, an additional sensitivity and specificity analysis was conducted using the Bootstrap method. The bootstrap method was applied by sampling, with replacement, from the original data set. Sampling was done on a per subject basis such that all records for a randomly chosen subject were extracted. One thousand data sets were generated using this method, each with the same number of subjects as the original data set.4444
A post hoc receiver operating characteristic (ROC) curve analysis was conducted to augment the description of diagnostic accuracy. ROC curves estimate and report all combinations of sensitivity and specificity the test is able to provide.4545 Results are expressed as a statistic, the “area under the curve” (AUC), a value ranging from 0 to 1 (ie, 0%‐100%) where 0.5 (ie, 50%) represents randomness. Values above 0.5 trend toward increasing diagnostic certainty for the test.
The measure for secondary endpoint (“time to detection”) was the number of days between pressure ulcer diagnosis by clinical judgment of the Specialist and the first day of measuring a delta (Δ) value ≥0.6.
The classic approach3030, 4646 to evaluating the accuracy of a diagnostic accuracy is to compare the results of the test under evaluation (index test) with the results of a reference standard; the best available method to determine the presence or absence of the condition or disease of interest. This reference standard is ideally, a “gold standard”, namely one that is without error. The performance of a new thermometer, for example, can be tested against an existing, objective measurement of temperature. A pure test for a new diagnostic device benefits from assessing a disease state that is not susceptible to being confounded by reversal or healing and can be objectively diagnosed, without error.
The rubrics of “sensitivity” and “specificity” do not neatly apply to the epistemological objectives central to this study, but nonetheless remain the paradigm statistical measures for a new diagnostic. The use of specificity as an end point was recognized, before study inception, as a worst‐case assessment for the SEM test because it classes all results in which a pressure ulcer did not visibly manifest (STA negative) but where changes in SEM were observed (SEM positive) as false positive results. No presently available alternative to the design was possible.
One‐hundred and eighty‐nine (n = 189) participants (46.7% males and 53.3% females) were enrolled, primarily from US sites (77.8% US vs 22.2% UK, respectively). Seven participants' data were not analyzable, resulting in an ITT population of 182 (Figure S4). The removal occurred before data analysis, which was performed following the a priori established statistical analysis plan. The reason for removal of six subjects' data was necessary because the delta values for each SEM reading point had been entered erroneously and could not be corrected by study staff or site monitors post hoc. One subject with an existing pressure ulcer (exclusion criteria, 1) was also erroneously enrolled into the study for 1 day and therefore did not meet eligibility. This was also a protocol deviation which was noted, reported and rectified by the principal investigator at the site.
With the exception of one site that used the Waterlow Scale, all study sites used the Braden scale for risk assessment as part of routine care. Demographic data are shown in Table 2.
|n||% or mean ± SD|
|Body mass index (kg/m2)|
|Total||182||26.8 ± 7.65|
|Male||85||27.4 ± 6.70|
|Female||97||26.2 ± 8.39|
|Total||182||76 ± 11|
|Male||85||73 ± 11|
|Female||97||79 ± 11|
|White or Caucasian||121||66.5%|
|American Indian/Alaskan Native||1||0.55%|
|Pacific Islander/Native Hawaiian||2||1.10%|
|Does not wish to provide||4||2.20%|
|Risk assessment scores|
|Very high risk (≤9)||15||9.04%|
|High risk1010, 1111, 1212||50||30.1%|
|Moderate risk1313, 1414||71||42.8%|
|Mild risk1515, 1616, 1717, 1818||20||12.1%|
|Not at risk (> 18)||2||1.20%|
|Very high risk (≥20)||5||31.3%|
|High risk1515, 1616, 1717, 1818, 1919||3||18.8%|
|At risk1010, 1111, 1212, 1313, 1414||6||37.5%|
|Not at risk (< 10)||2||12.5%|
STAs were performed on 437 unique anatomical locations (36.6%, n = 160 left heels; 36.4%, n = 159 right heels; and 27%, n = 118 sacral locations) during the course of the study. An interest in determining the existence or absence of differences in SEM readings between heels resulted in the preponderance of readings being at the heels. Additionally, some patients expressed emotional sensitivities to assessment of their sacral areas, which limited the number of sacral assessments. Applying PI staging per published guidelines,11 a total of 26% (n = 48/182) of the ITT population were diagnosed with a PI (Table 3), and the incidence by anatomical site was 11% (n = 48/437 (Table 5).
Table 4 provides a baseline skin profile of the enrolled subjects. Over 85% of the ITT population with available data were identified as having normal skin color and, a small percentage showed evidence of redness at the sacrum (12.60%), left heels (6.67%), and right heels (4.88%). Over 99% of the ITT indicated that the skin was blanchable at day 0. Enrollment data also show a majority of subjects were observed as having normal skin temperature, edema, induration, moisture, turgor, and health with no gross observations of bruising, cracked skin, abrasions, dehydration, pain; and moisture lesions were absent at the sacrum.
|Skin characteristics||ITT (N = 182)|
|Sacrum (n = 127)||Left heel (n = 165)||Right heel (n = 164)|
|Skin color||n (%)||n (%)||n (%)|
|Cyanosis||0 (0%)||1 (0.61%)||1 (0.61%)|
|Darker tone||2 (1.57%)||2 (1.21%)||2 (1.22%)|
|Normal color||109 (85.83%)||143 (86.67%)||144 (87.80%)|
|Paleness||3 (2.36%)||11 (6.67%)||11 (6.71%)|
|Redness||16 (12.60%)||11 (6.67%)||8 (4.88%)|
|Blanchable||126 (99.21%)||165 (100.0%)||164 (100.0%)|
|Nonblanchable||1 (0.79%)||0 (0%)||0 (0%)|
|Skin temperature—normal||116 (91.34%)||143 (86.67%)||144 (87.80%)|
|No edema||121 (95.28%)||141 (85.45%)||140 (85.37%)|
|No induration||126 (99.21%)||165 (100.0%)||163 (99.39%)|
|Skin moisture—normal||113 (88.98%)||134 (81.21%)||134 (81.71%)|
|Skin turgor—normal||125 (98.43%)||160 (96.97%)||158 (96.34%)|
|Tissue health—skin intact||125 (98.43%)||164 (99.39%)||164 (100.0%)|
|No other characteristics||119 (93.70%)||152 (92.12%)||149 (90.85%)|
|Pain free (score 0)||107 (84.25%)||107 (64.85%)||107 (65.24%)|
|Moisture lesion—absent||125 (98.43%)||0 (0%)||0 (0%)|
True positive, True Negative, False Positive, and False Negative classification results for the ITT population are shown in Table 5. In the ITT and PP populations, respectively, sensitivity relative to STAs was 87.5% (95% CI: 74.8%‐95.3%) and 84.2% (95% CI: 68.8%‐94.0%). Calculated specificity was 32.9% (95% CI: 28.3%‐37.8%) in the ITT population and 32.9% (27.0%‐39.3%) in the PP population. Using the Bootstrap method, sensitivity was 87.4% (95% CI: 77.8%‐96.7%) and specificity was 33% (95% CI: 27.6%‐38.7%). Incidence by anatomical site was 48/437 (11%). AUC for the ITT was 67.13% (95% CI: 59.7%‐74.6%). Positive predictive value (PPV) and negative predictive value (NPV) are the proportions of positive or negative results in diagnostic tests that are true positive and true negative results, respectively. For this SEM test, the PPV of SEM tests was 14%, and the NPV was 96%.
|ITT analysis (n = 182; total anatomical locations )|
|SEM Δ ≥ 0.6||42||261||13||61||29||200|
|SEMΔ < 0.6||6||128||3||41||3||87|
|Sensitivity||87.5% (74.8%‐95.3%)||81.3% (54.4%‐96.0%)||90.6% (75.0%‐98.0%)|
|Specificity||32.9% (28.3%‐37.8%)||40.2% (30.6%‐50.4%)||30.3% (25.1%‐36.0%)|
|Bootstrap sensitivity (all locations) 87.4% (95% CI: 77.8%–96.7%)|
|Bootstrap specificity (all locations) 33% (95% CI: 27.6%–38.7%)|
|ROCAUC 0.6713 (CI: 0.5969, 0.7457); P < .0001|
|Positive Predictive value (PPV) 14% (42/42 + 261)|
|Negative predictive value (NPV) 96% (128/6 + 128)|
|Per‐protocol analysis (n = 170)|
|SEM Δ ≥ 0.6||32||161||8||28||24||133|
|Sensitivity||84.2% (68.8%‐94.0%)||72.7% (39.0%‐94.0%)||88.9% (70.8%‐97.7%)|
|Specificity||32.9% (27.0%‐39.3%)||41.7% (27.6%‐56.8%)||30.7% (24.3%‐37.8%)|
The measure of analysis was the percentage of device‐related adverse events reported in the study. Adverse events in five enrolled subjects (2.6%) were reported. Four of the five were categorized by the principal investigators as unrelated to the study, with the remaining one being because of mortality from an underlying disease, also unrelated to the study. Of the 189 patients enrolled in the study, zero (0%) reports of adverse events were related to the use of the device or from prevention or treatments of PIs.
Early detection of PI by device measurements was analyzed using the true positive subset of PI results (ie, PI diagnosed by ΔSEM Δ ≥0.6 and by STA). For 42 true positive PIs in the ITT population, ΔSEM Δ ≥0.6 occurred 4.7 days ±2.4 days earlier than diagnosis by STAs (Figure S5). For the sacrum, left heel, and right heel, detection by the device preceded diagnosis by STA by 4.7 ± 2.6, 5.1 ± 2.3, and 4.3 ± 2.4 days, respectively.
Visible or palpable changes in skin characteristics identified during STAs were documented for all participants (Table 6). Some changes indicative of PI (eg, redness or warmth) were documented but were not associated with a diagnosis of PI.
|NPUAP/EPUAP/PPIA (2014, 1st ed.)||All||Sacrum||Heels|
|Red and nonblanchable skin||9||3||6|
|Red and blanchable skin||69||24||45|
|Other signs of skin changes (no PI)|
|Changes in skin temperature||58||14||44|
|Changes in skin firmness||13||3||10|
In this longitudinal, blinded clinical study, measurements of the SEM biomarker using the device demonstrated sensitivity of 87.5% in identifying PIs, relative to the reference standard of STA by wound care specialists. Additionally, the device produced a positive finding 4.74 days ±2.39 days earlier than the diagnosis of a PI by STA (Figure S5). These data agree with the temporal delay of 3‐10 days between SEM changes and the appearance of visible or palpable skin changes demonstrated in other studies.1616, 1717, 1818, 1919, 2020, 2121
This study did not meet the targeted endpoint for specificity of at least 55%. Two hundred and sixty‐one (n = 261) positive SEM deltas were classed as false positives resulting in a specificity approaching 33%. Given the comparison of nonvisual to visual skin damage, it is not surprising that a lower specificity is observed in this study. The Investigators considered a range of explanations for these specificity results.
Results from this study illustrate the difficulties inherent to diagnosis of PI by visible or palpable skin changes.5353, 5454 In the present study, controls were implemented to improve inter‐rater reliability, including the use of wound care specialists with accreditation in wound and ostomy or tissue viability care to perform protocol‐driven STAs. Nevertheless, a number of skin changes indicative of PI, particularly red and blanchable lesions, warmth/coolness, and firmness, were noted consistent with the second Edition of the 2014 international guidelines1111 but not diagnosed as PI (Table 6). The second edition and repeated in the 2019 international guidelines4343 suggests assessment of blanchable erythema and changes in sensation, temperature, or firmness may precede visual changes associated with a later stage 1 PI.
Subjects in this study were at PI risk and all were receiving universal prevention interventions, and in some instances, anatomy‐specific interventions. Blinding assured that no additional interventions were prescribed for patients as a result of positive SEM deltas. The clinical‐practice implications of the SEM false‐positive rate, while beyond the scope of this clinical trial, are important to consider. A positive SEM delta is an indicator that a patient's skin and tissue at the particular anatomy is exhibiting the signs of incipient damage which may progress toward a PI. For patients who have elevated SEM deltas, interventions may include more frequent anatomy‐specific offloading, a heel boot, 30° wedge, or prophalactic dressing.
False negative rates were low (n = 6; 3.3%). The risk of a false negative outcome is that a patient continues to receive the current standard of care. The likelihood of a false negative outcome is low based on this study results; patients will continue receiving standard of care interventions.
The AUC statistic of 67% shows a combined sensitivity and specificity of the test of SEM as one demonstrating clinical utility exceeding that of clinical judgment alone. Clinical judgment, as a unique diagnostic method, and as a collective term for STA combined with nurse interpretation, when plotted on the ROC curve is shown to the lower right side of the ROC curve for SEM data (Figure 1). Unique true‐positive, true‐negative, false‐positive, false‐negative results were not available for clinical judgment, hence the single plot of 1‐specificity (1‐60.1%) and sensitivity (50.6%).1313
The PPV of 14% is the proportion of true positive SEM deltas at heels and sacrum from the first SEM positive observation which later manifested into a confirmed PI. All SEM positive values preceded or coincided with PI diagnosis by STA. The same discussion points applicable to understanding the specificity percentage apply to the understanding the PPV percentage. Precision of the SEM test was potentially confounded by the preventative interventions necessarily applied to all patients. The negative predictive value of 96% is the proportion of true negative SEM deltas at heels and sacrum, which did not later manifest into confirmed PI. The 96% result suggests a higher certainty that normal SEM deltas (0.5 or less) in combination with prescribed preventative interventions will not result in a PI over the assessed anatomy, although such a result is not always true.
Future studies should assess alternative cut‐off delta values, particularly for anatomies with skin and tissue histology different to those found at heels and sacrum. Future interventional studies should explore the preventative effect of interventions precipitated by clinical judgment informed by SEM deltas. Formal Health Econonomic analyses should be undertaken to evaluate the cost consequences of the false positive rate, in particular.
Latency between the initial onset of pressure damage and the subsequent manifestation of a visible and clinically significant injury at the skin's surface, and the application of anatomy‐specific interventions has challenged clinical practice, and the objective of PI prevention for decades.5555 Of all reported Hospital Acquired Conditions, PIs are the only conditions to have worsened in the United States66 between 2012 and 2017, and they remain the most reported type of patient harm in the UK's National Health Service.5656 Keeping patient's tissue health is of critical clinical importance but remains a pernicious clinical challenge in patients who are at risk for PIs.
Sensitivity of the device exceeds that of visual STAs alone in its ability to detect the antecedents of a developing PI at the particular scanned anatomies. These results corroborate findings in other SEM studies.2020 Sensitivity and specificity of the SEM test in the aggregate as measured by the 67.13% area under the curve exceed that of clinical judgment alone. Even acknowledging specificity limitations, these data suggest that SEM biocapacitance measures can complement visual STAs, facilitate earlier identification of the risk of specific anatomies developing PIs, and inform earlier anatomy‐specific intervention decisions than visual STAs alone.
The use of specificity as an end point was recognized, before study inception, as a worst‐case assessment for the SEM test because it classes all results in which a PI did not visibly manifest (STA negative) but where changes in SEM were observed (SEM positive) as false positive results. Given proper ethical requirements of uninterrupted PI prevention protocols, which may have confounded specificity results in this study, future like studies require a different epistemological method to completely assess the specificity of SEM. An objective gold‐standard reference index test is required to perform such a test. Until such time and recognizing the false positive rate, these data suggest the clinical role of the device is in informing practitioners of anatomy‐specific PI risk where clinical judgment retains primacy over diagnosis.
Even though not all anatomies exhibiting elevated SEM deltas will proceed to eventually develop a PI, it is important for health‐care providers to be aware of the early warning signs so they can take risk‐appropriate mitigating steps. PI often occur without prior visual and palpable cues appearing in time to prevent them, especially if the injury is not superficial. Studies evaluating whether commencing PI prevention activities (eg, anatomy‐specific offloading) on the basis of positive SEM deltas as an adjunct to clinical judgment, rather than solely on risk and visual STAs have shown material reductions in the incidence of PIs.2626 As noted earlier, further analyses on prevention bundles and cost‐consequences are still necessary in future work.
Henry Okonkwo, Dr. Ruth Bryant and Jeanette Milne presented at Bruin Biometrics' sponsored symposia, for which they were paid speakers fees and reimbursed expenses by the Company.
Authors listed were Principal Investigators at each of their respective named sites. Each reviewed drafts of the manuscripts. The authors wish to acknowledge the following members of the study teams at individual sites who provided technical help but did not meet the requirements for authorship.
Bruin Biometrics, LLC., funded the clinical trial, and the authors received research support consistent with contracts engaged in between the Company and each trial site. Each site was reimbursed for all clinical trial expenses by Bruin Biometrics LLC.